Hospital
DLP Central Carolina Medical Center LLC
DLP Central Carolina Medical Center LLC was paid $11.98M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoDLP CENTRAL CAROLINA MEDICAL CENTER LLC
SANFORD, NC 27330
SANFORD, NC 27330
33aNPI1902836943assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.98M
24GClaims239,410
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#45 of 92
Median peer was paid$11.47M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,884 | $1.36M | |
| 2019 | 39,611 | $1.41M | |
| 2020 | 22,501 | $937K | |
| 2021 | 27,162 | $1.34M | |
| 2022 | 31,349 | $2.07M | |
| 2023 | 39,954 | $2.10M | |
| 2024incomplete | 42,949 | $2.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 32,487 | 28,079 | $3.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 19,919 | 16,608 | $3.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 4,074 | 3,279 | $861K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 7,196 | 6,335 | $523K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.9% | 407 | 380 | $466K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 8,760 | 6,971 | $268K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 2,906 | 2,434 | $236K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 5,605 | 4,317 | $188K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 7,372 | 5,887 | $187K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,497 | 3,779 | $166K |
| 80053 | Comprehensive metabolic panel | 1.2% | 18,167 | 14,905 | $147K |
| 87400 | 1.2% | 6,329 | 4,349 | $147K |
78 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 1,646 | $138K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 19,693 | $132K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 645 | $112K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 839 | $98K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,091 | $79K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,875 | $78K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 189 | $75K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,351 | $73K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,335 | $68K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,623 | $66K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,954 | $65K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 879 | $65K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,120 | $64K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,039 | $55K |
| 81001 | <1% | 17,785 | $54K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,453 | $52K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,442 | $37K |
| 81025 | <1% | 4,430 | $33K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,943 | $28K |
| 84484 | <1% | 3,682 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,047 | $24K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 607 | $21K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,858 | $17K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 431 | $16K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 570 | $15K |
| 84703 | <1% | 1,782 | $13K | |
| 83690 | <1% | 2,095 | $12K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 408 | $10K |
| 87420 | <1% | 609 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,195 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,036 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,350 | $7K |
| 83735 | <1% | 1,122 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 321 | $5K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,312 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $4K |
| 84702 | <1% | 331 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 140 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 54 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 376 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 184 | $3K |
| 82550 | <1% | 519 | $2K | |
| 85730 | <1% | 432 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 72 | $2K |
| 87430 | <1% | 100 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 139 | $1K |
| 85610 | <1% | 453 | $1K | |
| 85027 | <1% | 248 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 332 | $1K |
| 82553 | <1% | 180 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 109 | $1K |
| A9150 | Non-prescription drugs | <1% | 1,021 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 60 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 18 | $942.85 |
| 94664 | <1% | 61 | $848.65 | |
| 83605 | <1% | 127 | $776.04 | |
| 80076 | <1% | 147 | $740.08 | |
| J3490 | Unclassified drugs | <1% | 395 | $732.35 |
| J2704 | Injection, propofol, 10 mg | <1% | 116 | $727.14 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 162 | $580.58 |
| 87210 | <1% | 134 | $566.66 | |
| 87081 | <1% | 79 | $535.12 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 173 | $439.50 |
| 83880 | <1% | 15 | $320.51 | |
| 74018 | <1% | 13 | $283.36 | |
| 84100 | <1% | 69 | $254.06 | |
| 80305 | <1% | 26 | $233.57 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 247 | $215.93 |
| 82248 | <1% | 49 | $208.21 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 63 | $112.50 |
| 85379 | <1% | 16 | $101.83 | |
| 87070 | <1% | 15 | $63.78 | |
| 82948 | <1% | 19 | $39.45 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 26 | $21.60 |
| 82962 | <1% | 25 | $20.44 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 77 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.